BBY
41
-9
CMS
58
-2
EMN
52
-3
AIZ
52
2
DVA
47
-3
BMY
73
5
APH
58
2
CAG
34
-3
VIX
40
2
CF
48
3
ALL
57
-7
AAP
36
-5
CPB
37
-2
A
48
-3
ACN
56
-3
CL
56
-2
ETN
67
4
ES
45
5
AMGN
36
-3
CVS
44
4
BBY
41
-9
CMS
58
-2
EMN
52
-3
AIZ
52
2
DVA
47
-3
BMY
73
5
APH
58
2
CAG
34
-3
VIX
40
2
CF
48
3
ALL
57
-7
AAP
36
-5
CPB
37
-2
A
48
-3
ACN
56
-3
CL
56
-2
ETN
67
4
ES
45
5
AMGN
36
-3
CVS
44
4
Financhill
Back

Esperion Therapeutics, Inc. 10K Form

Buy
55

ESPR
Esperion Therapeutics, Inc.

Last Price:
$3.79
Seasonality Move:
30.02%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ESPR News And Ratings

See the #1 stock for the next 7 days that we like better than ESPR

ESPR Financial Statistics

Sales & Book Value

Annual Sales: $332.3M
Cash Flow: $-23.9M
Price / Cash Flow: 0
Annual Sales: $-2.20
Price / Book: 0

Profitability

EPS (TTM): -0.53580
Net Income (TTM): $-105.8M
Gross Margin: $263.7M
Return on Equity: 0%
Return on Assets: -31.23%

Esperion Therapeutics, Inc. Earnings Forecast

Key Esperion Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 18 years for ESPR is 79.36%.
  • The Selling, General & Administrative Expenses for ESPR have been equal to 49.07% of Gross Profit Margin.
  • The Research & Development expenses have been 13.91% of Revenue.
  • The Net Earning history of ESPR is -15.57% of Total Revenues.
  • Per Share Earnings over the last 18 years have been positive in 7 years.

Esperion Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ESPR
CUSIP: 29664W
Website: esperion.com

Debt

Debt-to-Equity Ratio: -1.32
Current Ratio: 1.15
Quick Ratio: 0.65

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 126.33

ESPR Technical Analysis vs Fundamental Analysis

Buy
55
Esperion Therapeutics, Inc. (ESPR) is a Buy

Is Esperion Therapeutics, Inc. a Buy or a Sell?